5 recruiting, 4 completed, 4 unknown, 1 active not recruiting. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Unknown 4, Completed 2 |
| Phase 1 | 7 | Unknown 3, Recruiting 2, Active not recruiting 1, Completed 1 |
Follow Transformed Lymphoma: new trials by email Literature Review of Transformed Lymphoma trials Research Report on Transformed Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| POLA-R-CHP in the First-line Treatment of Transformed DLBCL POLA-R-CHP - Transformed Lymphoma | Phase 2 | Recruiting | Fudan University | 20 | 2025-02-17 | 2025-02-25 |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Acalabrutinib - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 24 | 2023-01-23 | 2026-03-10 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | John Lister | 30 | 2022-04-19 | 2025-01-13 |
| DALY II USA/ MB-CART2019.1 for DLBCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 315 | 2021-05-25 | 2026-07-13 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Recruiting | C. Babis Andreadis | 36 | 2020-09-11 | 2026-10-26 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes Handgrip strength test, Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR), Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS) - Diffuse Large B Cell Lymphoma, Transformed Lymphoma | Completed | H. Lee Moffitt Cancer Center and Research Institute | 60 | 2020-03-10 | 2026-03-02 | |
| DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma Rituximab, Etoposide, Vincristine - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 118 | 2019-01-21 | 2022-01-26 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma BZ019 - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2018-06-08 | 2026-02-11 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma | Phase 2 | Completed | University of Maryland, Baltimore | 17 | 2017-10-23 | 2025-06-27 |
| Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma Rituximab 375 mg/m2 - Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma | Phase 2 | Completed | Stanford University | 35 | 1997-11-01 | 2014-09-15 |
Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, B-Cell (4) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Pyloric Stenosis, Hypertrophic (3) · Burkitt Lymphoma (2) · Lymphoma (2) · Recurrence (2) · Central Nervous System Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphoma (10) · Lymphoma, B-Cell (8) · Lymphoma, Non-Hodgkin (8) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (3) · Digestive System Diseases (3)
Cyclophosphamide (3) · Rituximab (3) · Automobiles (2) · Lenalidomide (2) · fludarabine (2) · Bendamustine Hydrochloride (1) · Cisplatin (1) · Costs and Cost Analysis (1) · Cytarabine (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Immunotherapy, Adoptive (1) · Neuropsychological Tests (1) · Quality of Life (1)
Huiqiang Huang (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · C. Babis Andreadis (1) · Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · John Lister (1) · Jonsson Comprehensive Cancer Center (1) · Miltenyi Biomedicine GmbH (1) · Stanford University (1) · University of Maryland, Baltimore (1) · Washington University School of Medicine (1)
United States (8) · China (6) · Canada (1)
Armin Ghobadi, M.D. (1) · Carrie Ho, MD (1) · Caspian Oliai, MD (1) · Dehui Zou, Dr. (1) · Fred Locke, MD (1) · Heather Jim, PhD (1) · Huiqiang Huang, Professor (1) · Jean Yared, MD (1) · Johanna Theruvath, MD (1) · John Lister, MD (1) · Lugui Qiu, MD (1) · Sandra J Horning, MD (1) · Yizhen Liu, M.D., Ph.D. (1)